INHIBITEX, INC.
- Headquarters
- Alpharetta, GA
- Latest Form D
- $23M, Nov 2009
- Total capital
- $23.1M
- Federal grants
- $125K
- 2 awards · 1999–2000
- Private capital raised
- $23M
- 1 Form D · last Nov 2009
- 204 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$23M
- Federal grantHealth and Human S · RC1 · Clinical Development Of Sa-igiv For S Aureus Infections$26K
- Federal grantHealth and Human S · Phase I · Adhesin Based Staphylococcal Immunotherapeutics$99K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
122months
from INHIBITEX, INC.’s first federal award to its first private round.
- First federal award · Sep 1999
- Health and Human S · $99K
- First Form D · Nov 2009
- $23M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Joseph M. PattiResearcherExecutive OfficerLinked by $125K in grants as PI
- A. Keith L. WillardDirectorNamed in SEC Form D filings
- Chris M. McGuiganDirectorNamed in SEC Form D filings
- Gabriele M. CerroneDirectorNamed in SEC Form D filings
- Geoffrey W. HensonExecutive OfficerNamed in SEC Form D filings
- Marc L. PremingerDirectorNamed in SEC Form D filings
Show all 10 people
- Michael M. HenosDirectorNamed in SEC Form D filings
- M. James M. BarrettDirectorNamed in SEC Form D filings
- Russell M. MedordDirectorNamed in SEC Form D filings
- Russell H. PlumbExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingCrystalline Solvates Of Nucleoside Phosphoroamidates, Their Stereoselective Preparation, Novel Intermediates Thereof, And Their Use In The Treatment Of Viral DiseaseUSPTOApplication PCTUS2012062772
- PendingPhosphoramidate Derivatives Of Guanosine Nucleoside Compounds For Treatment Of Viral InfectionsUSPTOApplication PCTUS2010020632
- PendingMonoclonal Antibodies Recognizing The Enterococcus Faecium Acm ProteinUSPTOApplication PCTUS2008051640
Show all 5 patent records
- Crystalline Solvates Of Nucleoside Phosphoroamidates, Their Stereoselective Preparation, Novel Intermediates Thereof, And Their Use In The Treatment Of Viral DiseaseApplication PCTUS2012062772Pending
- Phosphoramidate Derivatives Of Guanosine Nucleoside Compounds For Treatment Of Viral InfectionsApplication PCTUS2010020632Pending
- Monoclonal Antibodies Recognizing The Enterococcus Faecium Acm ProteinApplication PCTUS2008051640Pending
- Sdr Proteins From Staphylococcus Capitis And Their Use In Preventing And Treating InfectionsApplication PCTUS2004017039Pending
- Polysaccharide-staphylococcal Surface Adhesin Carrier Protein Conjugates For Immunization Against Nosocomial InfectionsApplication PCTUS2004006661Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .